Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Gastroenterology Reports

• Publication date

  2010-09-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11894-010-0141-0PMID 20882439PMCID PMC2974811
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis?

  2010cited by this paper
• Safety of Proton Pump Inhibitors: Current Evidence for Osteoporosis and Interaction with Antiplatelet Agents

  2010cited by this paper
• Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial

  2010influential reference
• A case series of proton pump inhibitor-induced hypomagnesemia.

  2010cited by this paper
• Cobalamin deficiency, hyperhomocysteinemia, and dementia

  2010cited by this paper
• Vitamin B12 Deficiency is Linked with Long-Term Use of Proton Pump Inhibitors in Institutionalized Older Adults: Could a Cyanocobalamin Nasal Spray be Beneficial?

  2010cited by this paper
• Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

  2010cited by this paper
• Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

  2010cited by this paper
• Safety of the long-term use of proton pump inhibitors.

  2010cited by this paper
• Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series.

  2010cited by this paper
• Adverse effects of proton pump inhibitors.

  2010cited by this paper
• Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients

  2009cited by this paper
• Long-term safety concerns with proton pump inhibitors.

  2009cited by this paper
• Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.

  2009cited by this paper
• Hypomagnesemia induced by several proton-pump inhibitors.

  2009cited by this paper
• Insights into the future of gastric acid suppression

  2009cited by this paper
• Proton Pump Inhibitors and Bone Fractures?

  2009cited by this paper
• Systematic review: impaired drug absorption related to the co‐administration of antisecretory therapy

  2009cited by this paper
• Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI

  2009cited by this paper
• The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism

  2009cited by this paper
• 414 Proton Pump Inhibitors, H2 Antagonists, and Risk of Hip Fracture: A Large Population-Based Study

  2009cited by this paper
• Erratum: Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI

  2009cited by this paper
• Hypomagnesaemia due to use of proton pump inhibitors--a review.

  2009cited by this paper
• Therapy: Another bad break for proton-pump inhibitors?

  2009cited by this paper
• Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo.

  2009cited by this paper
• Use of proton pump inhibitors and risk of osteoporosis-related fractures

  2008cited by this paper
• Does long-term PPI use result in vitamin B12 deficiency in elderly individuals?

  2008cited by this paper
• Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults

  2008cited by this paper
• Potential adverse effects of proton pump inhibitors

  2008cited by this paper
• Hip fracture and proton pump inhibitor therapy: position statement.

  2008cited by this paper
• Proton pump inhibitor therapy and osteoporosis.

  2008cited by this paper
• Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole

  2008cited by this paper
• Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

  2008cited by this paper
• Do We Need Gastric Acid?

  2008cited by this paper
• Do acid-lowering agents affect vitamin B12 status in older adults?

  2008influential reference
• Hip Fracture and Proton Pump Inhibitor Therapy: Balancing the Evidence for Benefit and Harm

  2008cited by this paper
• Proton pump-inhibiting drugs, calcium homeostasis, and bone health.

  2008cited by this paper
• Long-Term Proton Pump Inhibitor Use in Children: A Retrospective Review of Safety

  2008cited by this paper
• Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors

  2008cited by this paper
• Vitamin B12 deficiency in hypersecretors during long‐term acid suppression with proton pump inhibitors

  2008influential reference
• Omeprazole and refractory hypomagnesaemia

  2008cited by this paper
• [Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism?].

  2008cited by this paper
• Long‐term use of proton pump inhibitors and vitamin B12 status in elderly individuals

  2008influential reference
• Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

  2008cited by this paper
• Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis

  2007cited by this paper
• Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture

  2006influential reference
• Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.

  2006cited by this paper
• Long-term proton pump inhibitor therapy and risk of hip fracture.

  2006influential reference
• Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.

  2006cited by this paper
• Calcium absorption and achlorhydria.

  2006cited by this paper
• Review article: the long‐term use of proton‐pump inhibitors

  2005cited by this paper
• Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.

  2005cited by this paper
• Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans.

  2005cited by this paper
• Zollinger-Ellison syndrome revisited: Diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion

  2004cited by this paper
• Proton pump inhibitors and iron deficiency: is the connection real?

  2004cited by this paper
• Resolved and Unresolved Controversies in the Surgical Management of Patients With Zollinger-Ellison Syndrome

  2004cited by this paper
• Low Plasma Vitamin B12 Is Associated With Lower BMD: The Framingham Osteoporosis Study

  2004cited by this paper
• A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults.

  2004influential reference
• Effect of Omeprazole on Oral Iron Replacement in Patients with Iron Deficiency Anemia

  2004cited by this paper
• Increased Vitamin B12 Requirement Associated with Chronic Acid Suppression Therapy

  2003cited by this paper
• The stomach and iron deficiency anaemia: a forgotten link.

  2003cited by this paper
• Physiology and molecular biology of dietary iron absorption.

  2003influential reference
• Short-Term Omeprazole Treatment Does Not Influence Biochemical Parameters of Bone Turnover in Children

  2002cited by this paper
• Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats.

  2001cited by this paper
• Ingestion of guar-gum hydrolysate partially restores calcium absorption in the large intestine lowered by suppression of gastric acid secretion in rats

  1999cited by this paper
• Surgery to cure the Zollinger-Ellison syndrome.

  1999cited by this paper
• Surgery to cure the Zollinger-Ellison syndrome.

  1999influential reference
• Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome.

  1998cited by this paper
• Iron absorption in patients with Zollinger–Ellison syndrome treated with long‐term gastric acid antisecretory therapy

  1998cited by this paper
• Effect of L-lactic acid on calcium absorption in rats fed omeprazole.

  1998cited by this paper
• Chicken Parathyroid Hormone Gene Expression in Response to Gastrin, Omeprazole, Ergocalciferol, and Restricted Food Intake

  1997cited by this paper
• Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.

  1995cited by this paper
• Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.

  1995cited by this paper
• Vitamin B12 malabsorption and omeprazole therapy.

  1994cited by this paper
• Vitamin B12 malabsorption and omeprazole therapy.

  1994cited by this paper
• Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans

  1993cited by this paper
• Review article: metabolic consequences of long‐term inhibition of acid secretion by omeprazole

  1992cited by this paper
• Serum Iron, Ferritin, and Vitamin B12 During Prolonged Omeprazole Therapy

  1992cited by this paper
• Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract.

  1991cited by this paper
• The OMGE Recommendations for Education and Training in Gastroenterology, adapted to the Major Areas of the World Results of a Workshop held at the World Congresses of Gastroenterology, 25 August 1990, in Sydney, Australia

  1991cited by this paper
• Calcium absorption in elderly subjects on high- and low-fiber diets: effect of gastric acidity.

  1991cited by this paper
• Meal effects on calcium absorption.

  1989cited by this paper
• Omeprazole, a specific inhibitor of H+−K+-ATPase, inhibits bone resorptionin vitro

  1986cited by this paper
• An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.

  1984cited by this paper
• Role of gastric acid in food iron absorption.

  1981cited by this paper
• Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration

  1980cited by this paper

• Advancing pharmacist involvement in surgical prehabilitation: a call to action for global pharmacy practice.

  2026cites this paper
• Systematic analysis of proton pump inhibitors-related adverse reactions using the FDA adverse event reporting system database

  2026cites this paper
• Proton pump inhibitor use is not independently associated with colonic diverticulosis in an asymptomatic screening population

  2026cites this paper
• Pharmacovigilance study of the association between proton pump inhibitors and musculoskeletal and connective tissue disorders based on the FAERS database

  2025cites this paper
• Potenziell inadäquate Medikation im letzten Lebensmonat

  2025cites this paper
• The Effect of Proton Pump Inhibitors on Bone Mineralisation A Systematic Review with Focus on PHOSPHO1

  2025cites this paper
• Association Between Polypharmacy and Self-Reported Hearing Disability: An Observational Study Using ATC Classification and HHIE-S-It Questionnaire

  2025cites this paper
• Continuous PPI Treatment After Gastric Bypass Increases the Risk of Pathological PTH Levels at 10 Years Postoperatively

  2025cites this paper
• Current Medical Controversies in Zollinger–Ellison Syndrome

  2025cites this paper
• Integrative Strategies for Peptic Ulcer Disease: Therapeutic Synergy Between Conventional Treatments and Herbal Remedies in Helicobacter pylori Management

  2025cites this paper
• The effect of long-term proton pump inhibitor use on the visceral adiposity index

  2025cites this paper
• Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study

  2025cites this paper
• Phytoestrogens as Potential Anti-Osteoporosis Nutraceuticals: Major Sources and Mechanism(s) of Action.

  2025cites this paper
• DepRescribing inapprOpriate Proton Pump InhibiTors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care

  2025cites this paper
• Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High‐Dosage L. reuteri in H. pylori‐Infected Adults

  2025cites this paper
• The Impact of Proton Pump Inhibitor Use on Postoperative Complications in Anterior and Posterior Cervical Fusion Surgery: A Comparative Cohort Study

  2025cites this paper
• A Systematic Review of Long-Term Use of Proton Pump Inhibitors (PPIs) in Older Adults on Polypharmacy: Do PPIs Deplete Nutrients?

  2025cites this paper
• First assessments of nutrient bioaccessibility with an INFOGEST semi-dynamic gastric digestion in vitro protocol adapted to model proton pump inhibitor use.

  2025cites this paper
• Features of the state of bone tissue in children with cerebral palsy. Part 1. Etiological aspects. A literature review

  2024cites this paper
• Histopathological and biochemical evaluation of the protective efficacy of Prunus spinosa L. extract in a rat model of indomethacin-induced gastric ulcer

  2024cites this paper
• Drug-induced osteoporosis and mechanisms of bone tissue regeneration through trace elements.

  2024cites this paper
• Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks

  2024cites this paper
• Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence

  2024cites this paper
• How could proton pump inhibitors de-prescription be managed in geriatric long-term care?

  2024cites this paper
• Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study

  2024cites this paper
• Effect of proton pump inhibitors compared to histamine-2 receptor antagonists on bleeding management and wound healing after endoscopic mucosal resection or endoscopic submucosal dissection: A meta-analysis of randomized clinical trials.

  2024cites this paper
• Proton pump inhibitor use and bone fractures in patients with chronic kidney disease.

  2024cites this paper
• The combined use of anti-peptic agents is associated with an increased risk of osteoporotic fracture: a nationwide case-control study

  2024cites this paper
• Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR

  2024cites this paper
• Proton pump inhibitors and risk of severe COVID-19 in older people.

  2024cites this paper
• General approach to treatment of genetic leukoencephalopathies in children and adults.

  2024cites this paper
• Proton pump inhibitors, bone and phosphocalcic metabolism.

  2024cites this paper
• Multimorbidity patterns and trajectories in young and middle-aged adults: a large-scale population-based cohort study

  2024cites this paper
• Timely Cessation of Proton Pump Inhibitors in Critically Ill Patients Impacts Morbidity and Mortality: A Propensity Score-Matched Cohort Study*

  2024cites this paper
• Long-Term Proton Pump Inhibitor–Acid Suppressive Treatment Can Cause Vitamin B12 Deficiency in Zollinger–Ellison Syndrome (ZES) Patients

  2024cites this paper
• Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility

  2024cites this paper
• Mineral Supplements in Ageing.

  2024cites this paper
• Osseous implications of proton pump inhibitor therapy: An umbrella review

  2024cites this paper
• Nutritional Assessment of the Symptomatic Patient on a Plant-Based Diet: Seven Key Questions

  2023cites this paper
• Reducing Unnecessary Acid Suppression Use in Hospitalized Patients: A Description of Targeted Strategies Implemented Across a Large Health System.

  2023cites this paper
• Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.

  2023cites this paper
• Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES

  2023cites this paper
• Proton Pump Inhibitor Use and Risk of Dementia in Older Adults: A Systematic Review

  2023cites this paper
• Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship

  2023cites this paper
• Emerging factors affecting peri-implant bone metabolism.

  2023cites this paper
• Adverse Reaction Signals Mining of Vonoprazan: A Pharmacovigilance Study Based on FAERS

  2023cites this paper
• Association of proton pump inhibitor use with risk of kidney stones: an analysis of cross-sectional data from the US National Health and Nutrition Examination Survey (2007–2018)

  2023cites this paper
• An Unintended Case-Control Study: Corticosteroid Growth Restriction in a Monozygotic Twin

  2023cites this paper
• Progress in the Study of Vonoprazan Fumarate vs. Proton Pump Inhibitors in the Treatment of Gastroesophageal Reflux Disease

  2023cites this paper
• Evaluation of the Quality of Life in Pre- and Post-Operatory in Patients Submitted to Surgical Treatment of Reflux Disease and Hiato Hernia

  2023cites this paper
• Changes in Vitamin B12, Iron, Thyroid Hormones, Thyroid Autoantibodies and Hematological Indices Levels in Patients Suffering from Helicobacter pylori Infection

  2023cites this paper
• Nutrigenomics of inward rectifier potassium channels.

  2023cites this paper
• Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?

  2023cites this paper
• LAPAROSCOPIC ANTIREFLUX SURGERY: ARE OLD QUESTIONS ANSWERED? SHOULD IT BE USED CONJOINED WITH ENDOSCOPIC THERAPY FOR BARRETT’S ESOPHAGUS?

  2022cites this paper
• SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS.

  2022cites this paper
• Risk of urinary stone formation associated to proton pump inhibitors: A systematic review and metanalysis.

  2022cites this paper
• The Role of CCN1 in Esophageal Adenocarcinoma: What We Have Learned From the Lab

  2022cites this paper
• Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study

  2022cites this paper
• Medications to Avoid with Chronic Kidney Disease

  2022cites this paper
• The influence of proton pump inhibitors on tissue attachment around teeth and dental implants: A scoping review

  2022cites this paper
• Use of proton pump inhibitors for the risk of gastric cancer

  2022cites this paper
• O AUMENTO DO RISCO DE OSTEOPOROSE ASSOCIADA AO USO CRÔNICO DOS INIBIDORES DA BOMBA DE PRÓTONS: UMA REVISÃO BIBLIOGRÁFICA INTEGRATIVA

  2022cites this paper
• Acid-suppressive therapy among infants and risk of anemia at 12 months of age

  2022cites this paper
• Severe and Prolonged Hypocalcaemia Post Zoledronic Acid Infusion in a Patent with Sleeve Gastrectomy

  2022cites this paper
• Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease.

  2022cites this paper
• Radiodynamic Therapy with Acridine Orange Is an Effective Treatment for Bone Metastases

  2022cites this paper
• Role of Vitamin B6 and Folic Acid in Decreasing Diabetic Peripheral Sensory and Motor Neuropathy

  2022cites this paper
• Establishing the Association Between Osteoporosis and Peptic Ulcer Disease: A Systematic Review

  2022cites this paper
• Do proton pump inhibitors affect the biomechanical efficiency of implant?- a systematic review.

  2022cites this paper
• The Effects of Proton Pump Inhibitors in Acid Hypersecretion-Induced Vitamin B12 Deficiency: A Systematic Review (2022)

  2022influential citation
• [Thesaurus of pharmacist interventions associated with inappropriate proton pump inhibitors prescriptions].

  2022cites this paper
• Pharmacotherapy Problems in Best Possible Medication History of Hospital Admission in the Elderly

  2022cites this paper
• Nutritional Deficiencies in Morbid Obese Patients Before and After Laparoscopic Sleeve Gastrectomy

  2022cites this paper
• Rebuilding trust in proton pump inhibitor therapy

  2022cites this paper
• Cardiac Involvement in Patients with Gastroesophageal Reflux ‎Disease (GERD)

  2022cites this paper
• Implant-based oral rehabilitation in systemic sclerosis patients: a systematic review.

  2021cites this paper
• Костные нарушения при синдроме множественных эндокринных неоплазий 1-го типа: обзор клинических данных

  2021cites this paper
• Adverse Reactions of Proton Pump Inhibitors: A Literature Review

  2021cites this paper
• [The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)].

  2021cites this paper
• Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis

  2021cites this paper
• Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach

  2021influential citation
• Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature

  2021influential citation
• Proton pump inhibitors and mandibular bone quality: A preliminary study.

  2021cites this paper
• Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways

  2021cites this paper
• Food supplement vitamins, minerals, amino-acids, fatty acids, phenolic and alkaloid-based substances: An overview of their interaction with drugs

  2021cites this paper
• Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength

  2021cites this paper
• Characterization of bone homeostasis in individuals affected by cardio‐facio‐cutaneous syndrome

  2021cites this paper
• Treatment of NET-Related Symptoms

  2021cites this paper
• The role of magnesium supplement in laryngopharyngeal reflux disease

  2021cites this paper
• A Case of Lansoprazole-Induced Bullous Pemphigoid After Zantac Recall

  2021cites this paper
• Drug–Nutrient Interactions

  2021cites this paper
• Proton Pump Inhibitors Are Associated with Increased Risk of Psoriasis: A Nationwide Nested Case-Control Study

  2021cites this paper
• How Would You Manage This Patient With Nonvariceal Upper Gastrointestinal Bleeding?

  2021cites this paper
• Chinese expert consensus on gastroesophageal reflux disease in 2020

  2021cites this paper
• Medication use and dry eye symptoms: A large, hypothesis-free, population-based study in the Netherlands.

  2021cites this paper
• Adult North Star Network (ANSN): Consensus Guideline For The Standard Of Care Of Adults With Duchenne Muscular Dystrophy

  2021cites this paper
• Side effects of long-term use of proton pump inhibitors: practical considerations.

  2021cites this paper
• Effect of systemic administration of omeprazole on osseointegration around titanium dental implants: A histomorphometric study in dogs

  2021cites this paper
• Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target.

  2020cites this paper
• Diabetes Mellitus and Osteoporosis Correlation: Challenges and Hopes.

  2020cites this paper